Clinical Trial Update: Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating first-line treatment of relapsed or metastatic triple-negative breast cancer using albumin-bound paclitaxel in combination with antiang…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Antiangiogenic agent (unspecified)

Snippet

Sponsor: The First Affiliated Hospital of Bengbu Medical University | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: RECRUITING